Key milestones in the diabetes research: A comprehensive update

American Diabetes Association, 2004, Diagnosis and classification of diabetes mellitus, Diabetes Care, 1, S5, 10.2337/diacare.27.2007.S5

Aroda, 2017, Lancet Diabetes Endocrinol., 5, 355, 10.1016/S2213-8587(17)30085-2

Banach, 2013, Statin therapy and new-onset diabetes: molecular mechanisms and clinical relevance, Curr. Pharmaceut. Des., 19, 4904, 10.2174/1381612811319270014

Beals, 2019, Insulin, 403

Behl, 2017, Proposed mechanisms of Terminalia catappa in hyperglycaemia and associated diabetic complications, J. Pharm. Pharmacol., 69, 123, 10.1111/jphp.12676

Boudina, 2010, Diabetic cardiomyopathy, causes and effects, Rev. Endocr. Metab. Disord., 11, 31, 10.1007/s11154-010-9131-7

Carracher, 2018, International diabetes federation 2017, J. Diabetes, 10, 353, 10.1111/1753-0407.12644

Carter, 2013, Risk of incident diabetes among patients treated with statins: population-based study, BMJ, 346, f2610, 10.1136/bmj.f2610

Castaño, 2019, Exosomes and diabetes, Diabetes Metabol. Res. Rev., 35, 10.1002/dmrr.3107

Centers for Disease Control and Prevention, 2014

Chaudhery, 2017, Clinical review of antidiabetic drugs: implications for type 2 diabetes mellitus management, Front. Endocrinol., 8, 6

Cheang, 2018, Glucagon‐like peptide‐1 (GLP‐1)‐Based therapeutics: current status and future opportunities beyond type 2 diabetes, ChemMedChem, 13, 662, 10.1002/cmdc.201700781

Cool, 2006, Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome, Cell Metabol., 3, 403, 10.1016/j.cmet.2006.05.005

Danne, 2019, New insulins, biosimilars, and insulin therapy, Diabetes Technol. Ther., 21, S, 10.1089/dia.2019.2505

Davies, 2016, Current and emerging uses of statins in clinical therapeutics: a review, Lipid Insights, 9, LPI, 10.4137/LPI.S37450

Dey, 2017, SGLT2 inhibitor/DPP-4 inhibitor combination therapy–complementary mechanisms of action for management of type 2 diabetes mellitus, PGM (Postgrad. Med.), 129, 409, 10.1080/00325481.2017.1307081

DiSanto, 2015, Recent advances in nanotechnology for diabetes treatment, Wiley Interdiscip. Rev.: Nanomed. Nanobiotechnol., 7, 548

Farooq, 2018

FDA approved drugs (https://www.centerwatch.com/drug-information/fda-approved-drugs/year/2014) Accessed on 23-July-2019.

Florio, 2000, Activin A stimulates insulin secretion in cultured human pancreatic islets, J. Endocrinol. Investig., 23, 231, 10.1007/BF03343713

Forouhi, 2018, Dietary and nutritional approaches for prevention and management of type 2 diabetes, BMJ, 361, k2234, 10.1136/bmj.k2234

García-Romero, 2017, DNA sequences within glioma-derived extracellular vesicles can cross the intact Blood-Brain Barrier and be detected in peripheral blood of patients, Oncotarget, 8, 1416, 10.18632/oncotarget.13635

Gojo, 2007, The Rho-kinase inhibitor, fasudil, attenuates diabetic nephropathy in streptozotocin-induced diabetic rats, Eur. J. Pharmacol., 568, 242, 10.1016/j.ejphar.2007.04.011

Hardie, 2013, AMPK: a target for drugs and natural products with effects on both diabetes and cancer, Diabetes, 62, 2164, 10.2337/db13-0368

Hergenreider, 2012, Atheroprotective communication between endothelial cells and smooth muscle cells through miRNAs, Nat. Cell Biol., 14, 249, 10.1038/ncb2441

Hussain, 2004, Stem-cell therapy for diabetes mellitus, The Lancet, 364, 203, 10.1016/S0140-6736(04)16635-X

Kaku, 2018, Safety and efficacy of once-weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes: a randomized trial, Diabetes Obes. Metab., 20, 1202, 10.1111/dom.13218

Kaufmann, 2013, At el. Gene therapy on the move, EMBO Mol. Med., 5, 1642, 10.1002/emmm.201202287

Kawamura, 2004, High glucose-induced upregulation of osteopontin is mediated via Rho/Rho kinase pathway in cultured rat aortic smooth muscle cells, Arterioscler. Thromb. Vasc. Biol., 24, 276, 10.1161/01.ATV.0000112012.33770.2a

Lau, 2015, Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide, J. Med. Chem., 58, 7370, 10.1021/acs.jmedchem.5b00726

Luis-Rodríguez, 2012, Pathophysiological role and therapeutic implications of inflammation in diabetic nephropathy, World J. Diabetes, 3, 7, 10.4239/wjd.v3.i1.7

Marso, 2016, Semaglutide and cardiovascular outcomes in patients with type 2 diabetes, N. Engl. J. Med., 375, 1834, 10.1056/NEJMoa1607141

Massey, 2003, Increased RhoA translocation in renal cortex of diabetic rats, Life Sci., 72, 2943, 10.1016/S0024-3205(03)00228-5

Miao, 2002, Upregulation of small GTPase RhoA in the basilar artery from diabetic (mellitus) rats, Life Sci., 71, 1175, 10.1016/S0024-3205(02)01827-1

Mohammadi, 2015, Knowledge, attitude and practices on diabetes among Type 2 diabetic patients in Iran: a cross-sectional study, Science, 3, 520

Ofstad, 2013, Interleukin-6 and activin A are independently associated with cardiovascular events and mortality in type 2 diabetes: the prospective Asker and Baerum Cardiovascular Diabetes (ABCD) cohort study, Cardiovasc. Diabetol., 12, 126, 10.1186/1475-2840-12-126

Olson, 2008, Hepatic insulin gene therapy normalizes diurnal fluctuation of oxidative metabolism in diabetic BB/Wor rats, Mol. Ther., 16, 1235, 10.1038/mt.2008.97

Organization WH, 2000

Patel

Peng, 2008, RhoA/Rho-kinase contribute to the pathogenesis of diabetic renal disease, Diabetes, 57, 1683, 10.2337/db07-1149

Powell, 2019, Ertugliflozin: a new option in the sglt-2 inhibitor market for the treatment of type 2 diabetes mellitus, Ann. Pharmacother., 53, 478, 10.1177/1060028018818829

Pratley, 2018, SUSTAIN 7 Investigators. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial, Lancet Diabetes Endocrinol., 6, 275, 10.1016/S2213-8587(18)30024-X

Reusch, 2017, Management of type 2 diabetes in 2017: getting to goal, Jama, 317, 1015, 10.1001/jama.2017.0241

Ridker, 2008, Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein, N. Engl. J. Med., 359, 2195, 10.1056/NEJMoa0807646

Rikitake, 2005, Rho-kinase mediates hyperglycemia-induced plasminogen activator inhibitor-1 expression in vascular endothelial cells, Circulation, 111, 3261, 10.1161/CIRCULATIONAHA.105.534024

Sampson, 2011, Are statins diabetogenic?, Curr. Opin. Cardiol., 26, 342, 10.1097/HCO.0b013e3283470359

Scheen, 2017, Pharmacokinetic characteristics and clinical efficacy of an SGLT2 inhibitor plus DPP-4 inhibitor combination therapy in type 2 diabetes, Clin. Pharmacokinet., 56, 703, 10.1007/s40262-016-0498-9

Seino, 2018, Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes, Diabetes Obes. Metab., 20, 378, 10.1111/dom.13082

Shah, 2012, Statins and risk of new-onset diabetes mellitus, Circulation, 126, 10.1161/CIRCULATIONAHA.112.122135

Sorli, 2017, Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial, Lancet Diabetes Endocrinol., 5, 251, 10.1016/S2213-8587(17)30013-X

Sun, 2018, Human mesenchymal stem cell derived exosomes alleviate type 2 diabetes mellitus by reversing peripheral insulin resistance and relieving β-cell destruction, ACS Nano, 12, 7613, 10.1021/acsnano.7b07643

Tang, 2006, Increased RhoA translocation in aorta of diabetic rats, Acta Pharmacol. Sin., 27, 543, 10.1111/j.1745-7254.2006.00325.x

Tarr, 2013, Pathophysiology of diabetic retinopathy, ISRN Ophthalmol., 2013

Thomou, 2017, Adipose-derived circulating miRNAs regulate gene expression in other tissues, Nature, 542, 450, 10.1038/nature21365

Thulé, 2000, Regulated hepatic insulin gene therapy of STZ-diabetic rats, Gene Ther., 7, 1744, 10.1038/sj.gt.3301297

Tomlinson, 2016, An overview of new GLP-1 receptor agonists for type 2 diabetes, Expert Opin. Investig. Drugs, 25, 145, 10.1517/13543784.2016.1123249

Tsai, 2017, The Association between serum activin a levels and hypertension in the elderly: a cross-sectional analysis from I-Lan Longitudinal Aging Study, Am. J. Hypertens., 31, 369, 10.1093/ajh/hpx185

Viollet, 2009, Targeting the AMPK pathway for the treatment of Type 2 diabetes, Front. Biosci., 14, 3380, 10.2741/3460

Wang, 2015, Induction of human pancreatic beta cell replication by inhibitors of dual specificity tyrosine regulated kinase, Nat. Med., 21, 383, 10.1038/nm.3820

Whiting, 2011, IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030, Diabetes Res. Clin. Pract., 94, 311, 10.1016/j.diabres.2011.10.029

Wingard, 1995, Is insulin really a heart disease risk factor, Diabetes Care, 18, 10.2337/diacare.18.9.1299

Xu, 2018, Prevalence of diagnosed type 1 and type 2 diabetes among US adults in 2016 and 2017: population based study, BMJ, 362, k1497, 10.1136/bmj.k1497

Yechoor, 2009, Gene therapy with neurogenin 3 and betacellulin reverses major metabolic problems in insulin-deficient diabetic mice, Endocrinology, 150, 4863, 10.1210/en.2009-0527

Yechoor, 2005, Gene therapy progress and prospects: Gene therapy for diabetes mellitus, Gene Therapy, 12, 101, 10.1038/sj.gt.3302412

Ying, 2017, Adipose tissue macrophage derived exosomal miRNAs can modulate in vivo and in vitro insulin sensitivity, Cell, 171, 372, 10.1016/j.cell.2017.08.035

Zhang, 2009, AMPK: an emerging drug target for diabetes and the metabolic syndrome, Cell Metabol., 9, 407, 10.1016/j.cmet.2009.03.012

Zhao, 2018, Exosomes from adipose-derived stem cells attenuate adipose inflammation and obesity through polarizing M2 macrophages and Beiging in white adipose tissue, Diabetes, 67, 235, 10.2337/db17-0356

Zhu, 2017, PDX1, Neurogenin-3, and MAFA: critical transcription regulators for beta cell development and regeneration, Stem Cell Res. Ther., 8, 240, 10.1186/s13287-017-0694-z